{'fraction_non_alphanumeric': 0.017015706806282723, 'fraction_numerical': 0.014397905759162303, 'mean_word_length': 5.375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical Trials of Pharmacotherapy for Spinal Cord Injury

ABSTRACT: Spinal cord injury remains with limited natural recovery and only a few general ineffective treatment options. Recent publications have reported enhanced neurologic recovery with the use of methylprednisolone and GM‐1 ganglioside. The results of the Maryland GM‐1 Ganglioside Study reported a significant drug effect with respect to the fraction of patients that had a change of two or more Frankel grades from entrance into the study to 1‐year follow‐up. This study formed the basis for the currently ongoing larger placebo‐controlled multicentered study using Sygen® GM‐1 following acute spinal cord injury. This study has entered 797 patients and is expected to present results in early 1998.